Announcements Trials
Browse Landscape

Phase

Phase 2 92Phase 3 34Phase NA 10Phase 4 6Phase 1/2 6Phase 1 6Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 3Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 9OTHER 6NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 5Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 3Neoplasm Metastasis 2Solid Tumor 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Anastrozole × Clear all
NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT07163481 2025-09-16

SoGreat

Hunan Cancer Hospital

Phase 1 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

University of California, San Francisco

Phase 1 Completed
20 enrolled
Breast

Breast Neoplasms

NCT04316169 2022-12-23

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Medical College of Wisconsin

Phase 1 Withdrawn
BreastOther solid neoplasm

Solid Tumor

NCT01197170 2021-01-22

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

M.D. Anderson Cancer Center

Phase 1 Completed
277 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00588003 2015-12-24

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
45 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡